Exelixis Company Leadership
| EXEL Stock | USD 43.92 1.22 2.86% |
Exelixis' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Exelixis suggests that most insiders are panicking. Exelixis employs about 1.1 K people. The company is managed by 19 executives with a total tenure of roughly 75 years, averaging almost 3.0 years of service per executive, having 60.37 employees per reported executive.
| Michael Morrissey CEO CEO and President and Director |
| Stelios Papadopoulos Chairman Chairman and Member of Audit Committee |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-11-21 | Patrick J Haley | Disposed 28043 @ 42.58 | View | ||
| 2025-11-20 | Patrick J Haley | Disposed 34187 @ 41.88 | View | ||
| 2025-11-12 | Stelios Papadopoulos | Disposed 100000 @ 43.55 | View | ||
| 2025-11-11 | Mary C Beckerle | Disposed 24622 @ 41.93 | View | ||
| 2025-06-03 | Jack L Wyszomierski | Disposed 7535 @ 43.09 | View | ||
| 2025-06-02 | Sue Gail Eckhardt | Disposed 18838 @ 42.74 | View | ||
| 2025-05-21 | Tomas J Heyman | Disposed 4544 @ 44.29 | View | ||
| 2025-05-20 | Patrick J Haley | Disposed 34387 @ 44.06 | View | ||
| 2025-05-16 | George Poste | Disposed 20634 @ 45.99 | View | ||
| 2025-05-15 | Stelios Papadopoulos | Disposed 36508 @ 44.35 | View | ||
| 2025-05-14 | Patrick J Haley | Disposed 10000 @ 42.68 | View | ||
| 2025-05-01 | Dana Aftab | Disposed 1508 @ 39 | View | ||
| 2025-03-03 | Patrick J Haley | Disposed 10000 @ 38.8 | View | ||
| 2025-02-28 | Jack L Wyszomierski | Disposed 8768 @ 37.8 | View |
Monitoring Exelixis' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. Exelixis' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Exelixis' future performance. Based on our forecasts, it is anticipated that Exelixis will maintain a workforce of about 1150 employees by March 2026.Exelixis Management Team Effectiveness
The company has return on total asset (ROA) of 0.1926 % which means that it generated a profit of $0.1926 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3553 %, meaning that it created $0.3553 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.07. The value of Return On Capital Employed is expected to slide to 0.07. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Return On Tangible Assets will most likely fall to 0.07.Net Income Applicable To Common Shares is expected to rise to about 220.1 M this year, although the value of Common Stock Shares Outstanding will most likely fall to about 188.7 M. Exelixis holds a total of 259.71 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Also note that almost five million twelve thousand three hundred seventy-eight invesors are currently shorting Exelixis expressing very little confidence in its future performance.
Shares in Circulation | First Issued 1999-12-31 | Previous Quarter 278.5 M | Current Value 281.9 M | Avarage Shares Outstanding 181.9 M | Quarterly Volatility 107 M |
Exelixis Workforce Comparison
Exelixis is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 38,724. Exelixis holds roughly 1,147 in number of employees claiming about 2.96% of equities under Health Care industry.
Exelixis Profit Margins
The company has Profit Margin (PM) of 0.34 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.39 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.39.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.14 | 0.9604 |
|
|
Exelixis Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Exelixis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 1.0 | 4 | 4 | 956,633 | 239,569 |
| 2025-12-01 | 0.3571 | 5 | 14 | 215,707 | 617,611 |
| 2025-06-01 | 0.6207 | 18 | 29 | 819,533 | 1,621,661 |
| 2025-03-01 | 0.7838 | 29 | 37 | 3,152,268 | 1,075,672 |
| 2024-12-01 | 0.2308 | 6 | 26 | 1,002,386 | 2,171,397 |
| 2024-09-01 | 0.2857 | 4 | 14 | 320,000 | 746,540 |
| 2024-06-01 | 0.6957 | 16 | 23 | 683,574 | 288,514 |
| 2024-03-01 | 1.8889 | 17 | 9 | 1,441,661 | 224,205 |
| 2023-12-01 | 0.3333 | 3 | 9 | 287,302 | 445,471 |
| 2023-09-01 | 0.5 | 11 | 22 | 1,351,531 | 1,321,108 |
| 2023-06-01 | 1.6667 | 20 | 12 | 1,078,215 | 145,344 |
| 2023-03-01 | 0.4545 | 10 | 22 | 493,354 | 775,123 |
| 2022-12-01 | 0.2727 | 3 | 11 | 166,010 | 278,919 |
| 2022-09-01 | 0.875 | 7 | 8 | 478,419 | 285,776 |
| 2022-06-01 | 1.0909 | 12 | 11 | 305,861 | 230,808 |
| 2022-03-01 | 0.375 | 9 | 24 | 914,480 | 542,071 |
| 2021-12-01 | 0.3939 | 13 | 33 | 619,300 | 1,025,454 |
| 2021-09-01 | 0.7368 | 14 | 19 | 591,917 | 743,816 |
| 2021-06-01 | 0.8065 | 25 | 31 | 867,881 | 1,231,747 |
| 2021-03-01 | 0.7674 | 33 | 43 | 1,857,031 | 1,436,618 |
| 2020-12-01 | 0.3659 | 15 | 41 | 2,238,245 | 1,463,501 |
| 2020-09-01 | 0.6429 | 18 | 28 | 782,704 | 1,148,835 |
| 2020-06-01 | 0.6552 | 57 | 87 | 3,454,824 | 5,218,744 |
| 2020-03-01 | 0.5625 | 27 | 48 | 1,016,359 | 1,489,913 |
| 2019-12-01 | 0.3871 | 12 | 31 | 522,117 | 710,489 |
| 2019-09-01 | 0.5484 | 17 | 31 | 511,967 | 863,981 |
| 2019-06-01 | 1.2059 | 41 | 34 | 1,207,728 | 1,006,147 |
| 2019-03-01 | 0.4487 | 35 | 78 | 837,010 | 1,714,946 |
| 2018-12-01 | 0.175 | 7 | 40 | 130,146 | 466,213 |
| 2018-09-01 | 0.7083 | 17 | 24 | 1,517,131 | 1,229,228 |
| 2018-06-01 | 1.0 | 37 | 37 | 867,758 | 1,109,774 |
| 2018-03-01 | 0.5714 | 12 | 21 | 136,918 | 297,947 |
| 2017-12-01 | 1.2 | 12 | 10 | 1,437,500 | 21,781 |
| 2017-09-01 | 0.25 | 6 | 24 | 293,969 | 1,425,244 |
| 2017-06-01 | 1.0323 | 32 | 31 | 840,541 | 1,220,297 |
| 2017-03-01 | 0.4898 | 24 | 49 | 682,877 | 1,539,985 |
| 2016-12-01 | 0.5455 | 12 | 22 | 827,332 | 1,399,058 |
| 2016-09-01 | 2.6667 | 16 | 6 | 1,269,263 | 455,244 |
| 2016-06-01 | 21.0 | 21 | 1 | 1,535,000 | 200,000 |
| 2016-03-01 | 5.0 | 25 | 5 | 1,575,819 | 134,215 |
| 2015-12-01 | 0.8333 | 20 | 24 | 457,633 | 762,362 |
| 2015-09-01 | 9.0 | 18 | 2 | 3,912,000 | 170,000 |
| 2014-12-01 | 1.7778 | 16 | 9 | 563,565 | 13,891 |
| 2014-09-01 | 1.0 | 2 | 2 | 20,000 | 46,800 |
| 2014-06-01 | 3.0 | 9 | 3 | 360,000 | 13,000 |
| 2014-03-01 | 0.6364 | 7 | 11 | 242,268 | 15,169 |
| 2013-12-01 | 1.125 | 18 | 16 | 750,129 | 24,034 |
| 2013-09-01 | 1.1429 | 16 | 14 | 1,575,217 | 44,003 |
| 2013-06-01 | 1.3077 | 17 | 13 | 315,904 | 20,522 |
| 2013-03-01 | 0.5385 | 7 | 13 | 14,246 | 20,474 |
| 2012-12-01 | 0.75 | 18 | 24 | 77,333 | 52,836 |
| 2012-09-01 | 0.8125 | 13 | 16 | 1,031,454 | 61,940 |
| 2012-06-01 | 1.0 | 16 | 16 | 162,264 | 23,760 |
| 2012-03-01 | 0.5 | 6 | 12 | 12,267 | 50,054 |
| 2011-12-01 | 1.1667 | 7 | 6 | 212,265 | 12,265 |
| 2011-09-01 | 1.75 | 14 | 8 | 973,177 | 15,469 |
| 2011-06-01 | 2.2222 | 20 | 9 | 169,217 | 18,592 |
| 2011-03-01 | 1.0 | 9 | 9 | 74,376 | 74,376 |
| 2010-12-01 | 0.8182 | 9 | 11 | 104,427 | 157,216 |
| 2010-09-01 | 69.0 | 69 | 1 | 482,700 | 2,000 |
| 2010-03-01 | 2.0 | 2 | 1 | 70,000 | 8,000 |
| 2009-12-01 | 4.0 | 28 | 7 | 2,367,350 | 36,529 |
| 2009-09-01 | 1.5556 | 28 | 18 | 764,675 | 931,000 |
| 2009-06-01 | 1.2857 | 9 | 7 | 101,250 | 18,806 |
| 2008-09-01 | 1.0 | 1 | 1 | 185,000 | 0.00 |
| 2007-12-01 | 0.0455 | 7 | 154 | 1,225,000 | 30,625 |
| 2007-09-01 | 0.0345 | 2 | 58 | 90,000 | 18,125 |
| 2007-06-01 | 0.0427 | 10 | 234 | 92,108 | 44,841 |
| 2007-03-01 | 0.0106 | 2 | 188 | 65,000 | 150,000 |
| 2006-12-01 | 0.0486 | 9 | 185 | 1,064,000 | 32,500 |
| 2006-09-01 | 0.0048 | 1 | 209 | 175,000 | 32,500 |
| 2006-06-01 | 0.0727 | 20 | 275 | 135,624 | 153,748 |
| 2006-03-01 | 0.0199 | 5 | 251 | 13,971 | 56,449 |
| 2005-12-01 | 0.0354 | 8 | 226 | 2,340,000 | 112,500 |
| 2005-09-01 | 0.0476 | 1 | 21 | 60,000 | 278,486 |
| 2005-06-01 | 0.15 | 9 | 60 | 90,000 | 10,000 |
| 2005-03-01 | 0.0047 | 1 | 212 | 25,000 | 32,500 |
| 2004-12-01 | 0.0444 | 8 | 180 | 920,000 | 32,500 |
| 2004-09-01 | 0.0117 | 2 | 171 | 32,500 | 252,500 |
| 2004-06-01 | 0.1507 | 11 | 73 | 175,000 | 12,500 |
| 2004-03-01 | 0.0952 | 12 | 126 | 260,000 | 43,116 |
| 2003-12-01 | 0.0783 | 13 | 166 | 1,565,000 | 1,749,708 |
| 2003-09-01 | 0.0476 | 1 | 21 | 25,000 | 29,753 |
| 2003-06-01 | 0.7143 | 5 | 7 | 25,000 | 72,000 |
Exelixis Notable Stakeholders
An Exelixis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Exelixis often face trade-offs trying to please all of them. Exelixis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Exelixis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Morrissey | CEO and President and Director | Profile | |
| Stelios Papadopoulos | Chairman and Member of Audit Committee | Profile | |
| Susan Hubbard | Executive Vice President - Public Affairs and Investor Relations | Profile | |
| Christopher Senner | CFO, Executive Vice President | Profile | |
| Peter Lamb | Chief Scientific Officer and Executive VP of Discovery Research | Profile | |
| Stefan Krauss | VP Development | Profile | |
| Laura Dillard | Executive Resources | Profile | |
| Tony Redmond | Senior Resources | Profile | |
| Brenda JD | General Counsel | Profile | |
| Gregg Bernier | VP Marketing | Profile | |
| William MD | Senior Affairs | Profile | |
| Amy MD | Executive Officer | Profile | |
| Patrick MBA | Executive Commercial | Profile | |
| Dana Aftab | Executive Development | Profile | |
| Jeffrey JD | Executive Counsel | Profile | |
| Anne MD | Senior Safety | Profile | |
| Andrew Peters | Senior Strategy | Profile | |
| MBA MBA | Ex Commercial | Profile | |
| Deborah CPA | Senior Controller | Profile |
About Exelixis Management Performance
The success or failure of an entity such as Exelixis often depends on how effective the management is. Exelixis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Exelixis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Exelixis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.28 | 0.07 | |
| Return On Capital Employed | 0.36 | 0.07 | |
| Return On Assets | 0.28 | 0.07 | |
| Return On Equity | 0.36 | 0.09 |
Exelixis Workforce Analysis
Traditionally, organizations such as Exelixis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Exelixis within its industry.Exelixis Manpower Efficiency
Return on Exelixis Manpower
| Revenue Per Employee | 2M | |
| Revenue Per Executive | 122.1M | |
| Net Income Per Employee | 682.3K | |
| Net Income Per Executive | 41.2M | |
| Working Capital Per Employee | 904.7K | |
| Working Capital Per Executive | 54.6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.842 | Earnings Share 2.86 | Revenue Per Share | Quarterly Revenue Growth 0.056 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.